G. Kaufmann

发表

Safety and efficacy of a two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model.

W. Haefeli, S. Vožeh, M. Wenk, 1998, Therapeutic drug monitoring.

N‐Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus

W. Haefeli, U. Meyer, K. Gyr, 1996, Clinical pharmacology and therapeutics.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

M. Battegay, H. Furrer, P. Vernazza, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals

R. Weber, M. Battegay, P. Vernazza, 2009, HIV clinical trials.

Persistent Apoptosis in HIV-1-Infected Individuals Receiving Potent Antiretroviral Therapy Is Associated With Poor Recovery of CD4 T Lymphocytes

R. Weber, M. Battegay, P. Erb, 2004, Journal of acquired immune deficiency syndromes.

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death

R. Weber, M. Battegay, H. Furrer, 2011, AIDS.

Immune reconstitution in HIV-infected patients.

M. Battegay, H. Hirsch, P. Sendi, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

D. Cooper, J. Zaunders, M. Bloch, 2000, AIDS.

Primary HIV-1 infection: a review of clinical manifestations, immunologic and virologic changes.

D. Cooper, C. Duncombe, J. Zaunders, 1998, AIDS patient care and STDs.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

A. Telenti, M. Egger, M. Battegay, 2003, Archives of internal medicine.

CD 4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study

A. Telenti, M. Egger, M. Battegay, 2003 .

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

D. Cooper, D. Chisholm, K. Samaras, 1999, The Lancet.

Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options.

D. Cooper, G. Kaufmann, 2000, Current opinion in microbiology.

Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.

D. Cooper, J. Zaunders, G. Kaufmann, 1999, AIDS research and human retroviruses.

Year : 2008 CD 4 + T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy

R. Weber, M. Battegay, H. Furrer, 2009 .

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

R. Weber, M. Battegay, H. Furrer, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD4+ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy

M. Battegay, H. Furrer, P. Vernazza, 2007, Antiviral therapy.

Immunological recovery and antiretroviral therapy in HIV-1 infection.

M. Battegay, B. Hirschel, G. Kaufmann, 2006, The Lancet. Infectious diseases.

Productivity costs and determinants of productivity in HIV-infected patients.

R. Weber, M. Battegay, H. Bucher, 2004, Clinical therapeutics.

Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection

R. Weber, M. Battegay, H. Furrer, 2004, Antiviral therapy.

Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection

D. Cooper, A. Kelleher, J. Zaunders, 2000, AIDS.

Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.

D. Cooper, A. Kelleher, J. Zaunders, 2001, AIDS research and human retroviruses.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

D. Cooper, J. Zaunders, M. Bloch, 2002, AIDS.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy

R. Weber, M. Battegay, M. Opravil, 2007, AIDS.

CD4+ CCR5+ T-Cell Dynamics during Simian Immunodeficiency Virus Infection of Chinese Rhesus Macaques

G. Silvestri, J. Estaquier, V. Monceaux, 2007, Journal of Virology.

Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV‐1‐infected individuals

D. Cooper, C. Duncombe, M. French, 1998, AIDS.

Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection.

M. Battegay, T. Klimkait, G. Kaufmann, 2002, The Journal of infectious diseases.

Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group.

D. Cooper, J. Zaunders, M. Law, 1999, Journal of acquired immune deficiency syndromes.

Hepatitis C Virus Core Mutations Reduce the Sensitivity of a Fluorescence Enzyme Immunoassay

D. Cooper, H. Harada, G. Kaufmann, 2000, Journal of Clinical Microbiology.

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.

D. Cooper, A. Kelleher, J. Zaunders, 1998, The Journal of infectious diseases.

Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection1 2

Alan S. Perelson, Ruy M. Ribeiro, John Zaunders, 2002, The Journal of Immunology.

Effect of Antiretroviral Therapy on Apoptosis Markers and Morphology in Peripheral Lymph Nodes of HIV-Infected Individuals

F. Gudat, M. Battegay, G. Pantaleo, 2008, Infection.

Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

D. Cooper, J. Zaunders, G. Kaufmann, 1999, Sexually transmitted infections.

Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

D. Cooper, J. Zaunders, M. Imai, 2001, AIDS research and human retroviruses.

Gynecomastia and potent antiretroviral therapy.

M. Battegay, M. Cavassini, G. Kaufmann, 2004, AIDS.

Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.

D. Cooper, J. Zaunders, P. Grey, 2001, The Journal of infectious diseases.

Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries

M. Battegay, D. Cooper, P. Phanuphak, 2002, Expert opinion on investigational drugs.

Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty

Anthony D Kelleher, S. Lewin, M. Davenport, 2003, Immunology and cell biology.

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.

D. Cooper, A. Kelleher, J. Zaunders, 1999, The Journal of infectious diseases.

Chronic HIV Infection Circles Differ After Treatment of Acute and Dynamics of T Cells and TCR Excision

Ajantha, A. Perelson, S. Lewin, 2002 .

Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling.

S. Lewin, D. Cooper, A. Kelleher, 2001, AIDS research and human retroviruses.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

A. Telenti, M. Egger, M. Battegay, 2003, Archives of internal medicine.

Fatal Acute Varicella-Zoster Virus Hemorrhagic Meningomyelitis with Necrotizing Vasculitis in an HIV-Infected Patient

M. Battegay, N. Khanna, G. Kaufmann, 2009 .

Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.

J. Kahn, F. Hecht, D. Cooper, 2003, AIDS research and human retroviruses.